INTRODUCTION 11 12
The CRISPR/Cas9 systems has revolutionized genome editing in many model 13 and non-model organisms. Because of its high efficiency and simplicity of target design, 14 CRISPR/Cas9 is now being used for a wide variety of molecular biology applications 15 (Sander and Joung 2014). The technique was simplified with the use of single guide 16
RNAs (sgRNA) containing a target site and chimeric crRNA and tracrRNA sequences 17 that can direct Cas9 to the target site (Hsu et al. 2014) . Target recognition only requires 18 the presence of a protospacer adjacent motif (PAM) at the 3' end of the target site. The 19 widely used Cas9 protein from Streptococcus pyogenes (SpCas9) utilizes a G-rich, 20 NGG PAM sequence that limits the selection of target sites, however, Cas9 orthologs 21 and engineered Cas9 variants that recognize other PAM sequences have expanded the 22 set of available target sites. Still more target sites are available with the recently 23 identified CRISPR/Cpf1 class of proteins (Zetsche et al. 2015) . Similar to Cas9 proteins, 24 Cpf1 proteins are single RNA-guided endonucleases, but they function without 25 tracrRNA and recognize a T-rich PAM. While an entire family of Cpf1 proteins was 26 discovered, only two Cpf1 proteins, from Acidaminococcus (AsCpf1) and 27 Lachnospiraceae (LbCpf1), have been shown to work for mammalian genome editing in 28 vitro. Both AsCpf1 and LbCpf1 recognize a TTTN PAM site that could be useful in 29 targeting regulatory regions or AT-rich genomes. Two groups have recently reported 30 Cpf1 activity in mice, although with variable targeting rates and 3 different methods to deliver the Cpf1 into mouse zygotes including pronuclear microinjection of ribonuclear-1 protein complexes (RNPs), electroporation of RNPs, or cytoplamasmic microinjection of 2 mRNA/gRNA mixtures (Hur et al. 2016; Kim et al. 2016) . Here, we report the first 3 demonstration of AsCpf1 activity using a distinct delivery method, pronuclear 4 microinjection of RNA, show the targeting rate with this delivery method is highly 5 dependent on RNA concentration, and that multiple tested target sequences and 6 conditions were ineffective for targeting in zebrafish embryos. To test if AsCpf1 had activity following pronuclear injection and if the targeting 12 rate of AsCpf1 for in vivo gene knockout in mouse is affected by RNA concentration, 13
Exon 1 of Tyrosinase (Tyr) was targeted with two different gRNAs ( Figure 1A) . The 14 gRNAs were injected individually, or co-injected as a pair along with AsCpf1 RNA for 15 pronuclear injection at either a "low" concentration (10ng/µl Cpf1 with 2.5ng each 16 gRNA,) comparable to concentrations routinely used for Cas9 targeting, or a "high" 17 concentration (50ng/µl with 100ng each gRNA). In total, 297 founders were screened 18 following 13 injection sessions carried out in parallel to compare the targeting rate 19 following injection of low or high concentrations of gRNA and Cpf1 RNA (Supplemental 20 Table 1 ). Among the founder mice that were carried to term to allow for phenotype 21 screening after birth, albino mice as well as mosaic mice with visible patches of albino 22 hair were observed, phenotypes consistent with efficient targeting of the wild-type 23 C57BL/6J Tyr allele in the hybrid C57BL/6J x FVB/N F1 mice ( Figure 1B) . The 297 24 founder mice were initially genotyped by sizing a fluorescently labeled PCR product 25 spanning the two target sites to detect potential indels at any sites of DNA cleavage 26 using both low resolution agarose gels and high resolution capillary electrophoresis 27 (Supplemental Figure 1 ). In total, PCR products that differed from the expected 351bp 28 wild-type product were detected in 73/297 founder mice, indicating that indels occurred 29
with an overall frequency of 24.6%. Importantly, injection sessions with a high RNA 30 concentration resulted in a much higher targeting rate (73.3% of the founders) compared to those with a low RNA concentration (3.4% of the founders) (Supplemental 1 Table 1 ). Because of the overall high efficiencies of targeting with two guides at the high 2 RNA concentration and small number of founders, we could not make conclusions 3 about any effect the direction of the cross had on the targeting rate ((C57BL/6J female x 4 FVB/N male) vs (FVB/N female x C57BL/6J male)) ( Supplemental Table 2 ). However, in 5 the low concentration injections, we observed a significantly higher targeting rate with 6 C57BL/6J fertilized eggs (C57BL/6J female x FVB/N male) compared to the reciprocal 7 cross (Supplemental Table 2 ). Importantly, the high concentration injections were more 8 efficient independent of the direction of the cross (Supplemental Table 3 ). 9
To further characterize the AsCpf1-mediated indels, a combination of deep 10 sequencing (Illumina MiSeq) and Sanger sequencing was carried out on PCR products 11 spanning the target sites. This sequencing revealed that there was only one Target B 12 site mutation; all other mutations were localized to the gRNA Target A site. 13
Furthermore, in the more efficient high concentration injections, a higher targeting rate 14 per 100 founders was observed at the Target A site when Target B was co-injected with 15 87.1% (54/62) of founders targeted following co-injection vs 42.8% (12/28) following 16 single gRNA injected (Fisher's test P<0.0001). While confirmation is needed from 17 additional experiments, this intriguing result suggests that co-injection of multiple 18 gRNAs may increase AsCpf1 activity. 19
In the low concentration injections, the majority of mice were wild-type (97%), 20 and very few heterozygote or mosaic mice were generated that carried one (2%) or two 21 (1%) mutant alleles. In contrast, the high concentration injections had both a higher rate 22 of mutation and also a higher rate of mosaicism, with 5% of the founder mice each 23 carrying as many as 5 different mutant alleles ( Figure 1C ). In total, 74 different alleles 24 were identified in the 52 mutant founder mice that were fully characterized by deep 25 sequencing. The majority of these alleles (71%) arose only in a single founder, 26 however some alleles (29%) were reoccurring, as 9 alleles arose independently in 4 or 27 more founder mice ( Figure 1D ). As expected, approximately 2/3 of the alleles 28 introduced a frameshift ( Figure 1E ). The indels ranged in size from -60bp to +15bp and 29 were mostly deletion alleles ( Figure 1F and Supplemental Figure 2 ), consistent with 30 observations in Drosophila melanogaster (Port and Bullock 2016) . All of the founder mice were confirmed to be heterozygous for a SNP (rs31191169) known to be 1 polymorphic between C57BL/6J and FVB/N that is located 195bp proximal to the Target 2 A site, indicating that no large deletions occurred that extended beyond the PCR 3 amplicon used for sequencing. 4
The majority of the founder mice appeared mosaic, as indicated by an uneven 5 ratio of alleles within the PCR product where one or more mutant alleles were detected 6 at less than the expected 50%. This result is consistent with the mosaic coat color 7 pattern observed in founder mice carried to term and indicates that DNA cleavage often 8 occurred after the one cell stage. Because of this high frequency of mosaic founders, 9 germline transmission of the AsCpf1-induced mutant alleles was confirmed by breeding 10 6 founder mice to FVB/N. One of these founders was albino and 5 were mosaic with a 11 range of 10-70% estimated albino coat color contribution, representing a wide range of 12 the observed mosaicism including the lowest and highest contribution founders 13 (Supplemental Figure 3 ). In all 6 mice, the Cpf1-mediated mutant allele was transmitted 14 and in one mosaic mouse, two different mutant alleles were transmitted. 15
In contrast to mouse, we were unable to successfully induce gene knockout in 16 zebrafish with AsCpf1. Using injection methods previously successful with Cas9 17 (Varshney et al. 2015) , we targeted 6 genes with 40 different targets (23nt or 24nt), but 18 no activity was detected by CRISPR- STAT (Carrington et al. 2015) . These results 19 suggest that either AsCpf1 has lower activity in zebrafish than Cas9 or that there are 20 unique technical requirements for AsCpf1 activity in this species. 21
In summary, we detected AsCpf1 activity in mouse, but not in zebrafish. The 22 level of AsCpf1 activity in mouse zygotes was highly dependent on RNA concentration 23 and at high concentrations was extremely effective, confirming that AsCpf1 provides an 24 excellent alternative to Cas9 for the generation of knockout mice. Our targeting rate 25 with AsCpf1 at high RNA concentrations (42-100% of founders) is significantly higher 26 than at low RNA concentrations (0-21%) and is consistent with other studies that used a 27 variety of delivery methods for Cpf1-medicated targeting in mice. For comparison, 28 Table 4 ).
Our "high" concentration is comparable to that published for cytoplasmic microinjection 1 of RNA (Kim et al. 2016) , however much higher than required for Cas9 activity with 2 pronuclear microinjections which typically are performed using lower RNA 3 concentrations than cytoplasmic microinjections (Singh et al. 2015) . Because of the 4 different delivery methods and limited number of guides tested, few conclusions can be 5 drawn about the most important variables affecting the AsCpf1 targeting rate in mice, 6 which may include RNA concentration, mouse strain, delivery method, or local target 7 sequence. Importantly, our study provides the first direct comparison of a guide RNA at 8 different concentrations and suggests that Cpf1 is ineffective for targeting at an RNA 9 concentration that is effective for Cas9 in our laboratory and others (Mashiko et al. 10 2013 , Yang et al. 2013 , Horii et al. 2014 . Interestingly, we observed that targeting was 11 more efficient with co-injection of two adjacent guides, even though one guide was 12 essentially inactive. While this represents data from only a single locus, the statistically 13 significance (P<0.0001) indicates that the effect of co-injection on targeting rate is worth 14 testing more broadly in the future. 15
Because the T-rich PAM sequences recognized by AsCpf1 differ from Cas9, the 16 combination of these nucleases will permit the precise targeting necessary for knock-in 17 projects, especially those aimed at modeling short sequence variants at particular 18 genomic locations. Also, the shorter size of the gRNA utilized by AsCpf1 provides an 19 advantage over Cas9 for reducing the cost of RNA oligonucleotide synthesis and has 20 the potential to improve efficiency of gRNA delivery. Importantly, the frequency of 21 homology-directed repair or ligation-mediated insertion by Cpf1 remains to be 22 determined and could yet provide the largest advantage for Cpf1 over Cas9. Laboratories; abbreviated B6) females approximately 9 hours after mating with 17 C57BL/6J or FVB/N males, respectively. Microinjections were performed using a 18 capillary needle with a 1-2um opening pulled with a Sutter P-1000 micropipette puller. 19
The pronucleus was injected using a FemtoJet 4i (Eppendorf) with continuous flow that 20 we estimate to result in approximately 2pl of injection mix. Following visualization of 21 pronuclear swelling, the needle was pulled out through the cytoplasm, likely resulting in 22 a small amount of additional RNA delivery to the cytoplasm. Injected eggs were 23 surgically transferred to pseudopregnant CB6F1 hybrid recipient females, bred at the 24 NIH from a cross of Balb/cJ females to C57Bl/6J males. In general, the injection mix 25 contained AsCpf1 RNA and gRNA diluted in 10mM Tris, 0.25mM EDTA (pH 7.5). 26
Specific RNA and DNA concentrations for each injection session are provided 27 (Supplemental Table 1 ). 28 29 Mouse husbandry: All animal procedures were performed in a pathogen-free, 1 AAALAC-approved facility in accordance with NIH guidelines and approved by the 2 NHGRI Animal Care and Use Committee (ACUC). 3 4 Genotyping: Founder animals were screened using a combination of PCR and 5 sequencing as previously described (Varshney et al. 2015) . Briefly, DNA was extracted 6 from midgestation whole embryos or pup tail biopsies and purified using a Gentra 7
Puregene Mouse Tail Kit (Qiagen). A PCR product spanning both gRNA target sites 8 was generated using a Tyr-specific forward primer with an M13-tail 9
(tgtaaacgacggccagtTCTATGTCATCCCCACAGGCAC) and a Tyr-specific reverse 10 primer containing a pig-tail (gtgtcttGGTGACGACCTCCCAAGTACTC). The PCR 11 product was amplified with the addition of a 6-FAM or HEX labeled M13-forward 12 oligonucleotide and run on an ABI 3130xl with ROX400 or ROX500 size standards to 13 detect small indels (<50bp) at single base pair resolution. Standard agarose gels were 14 also used to screen PCR products for larger indels (>20bp) including possible deletion 15 of the 116bp between the two guides which was never observed. 16
17
A subset of founders with PCR product sizes that differed from wild-type were further 18 characterized by Sanger sequencing of total PCR products or subcloned PCR products 19 generated with additional gene specific primers. Additionally, selected founders were 20 characterized with deep sequencing using PCR products generated with Tyr-specific 21 primers (tgtaaaacgacggccagtTTTTCTTACCTCACTTTAGCAAAACA and 22
GGATGCTGGGCTGAGTAAGT) along with the barcoded third primer set, as described 23 2015 Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. 13
Cell 759-771. 14 independent PCR product (red *). For mutant alleles, the size of each allele relative to 6 wild-type is indicated along with the percentage of sequencing reads. Note that founder 7 11.6 lacks a wild-type allele. Upon sequencing, we determined that the single -7bp 8 peak in founder 9.6 was actually a mix of two different -7bp mutant alleles. Similarly the wild-type Tyrosinase sequence. The target site is indicated (red) along with deleted 5 bases (-) and inserted or altered bases (lower case). Note that in some cases the exact 6 breakpoint cannot be determined from the sequence data because bases on either side 7 of the breakpoint are identical. For each allele, the number of founder mice observed 8 carrying that allele is indicated along with the percentage of sequencing reads within the 9 founder PCR product. For alleles observed in multiple founders, a range of percentages 10 is given. 11 
